Organization
Rheumatology, U. Chicago, Chicago
1 abstract
Abstract
78-WEEK SAFETY DATA FROM THE RANDOMIZED, DOUBLE-BLIND PHASE II/III EXPLORER STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TREATED WITH RITUXIMAB Org: Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma, Internal Medicine, U. Kansas, Kansas, Rheumatology, U. Chicago, Chicago, Rheumatology, N. Shore LIJ Health System, Lake Success, Rheumatology, Alameda Medical Ctr, Oakland,